Back to Journals » Cancer Management and Research » Volume 13

Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic

Authors Chauhan AF, Cheson BD

Received 3 October 2020

Accepted for publication 30 December 2020

Published 25 January 2021 Volume 2021:13 Pages 677—692


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Antonella D'Anneo

Video abstract presented by Ayushi F Chauhan.

Views: 48

Ayushi F Chauhan,1 Bruce D Cheson2

1Department of Hematology and Oncology, Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington DC, USA; 2Scientific Advisory Board, Lymphoma Research Foundation, Washington, DC, USA

Correspondence: Ayushi F Chauhan Email

Abstract: The phosphatidylinositol-3-kinase (PI3K) pathway is ubiquitous to multiple cellular processes and is intricately implicated in lymphomagenesis. The development of PI3K inhibitors has broadened treatment options for relapsed and/or refractory follicular lymphoma (FL) and currently three PI3K inhibitors have been approved in the third-line setting for FL, including idelalisib (oral), duvelisib (oral), and copanlisib (intravenous), with other agents under investigation. In this review, we discuss the clinical advance of copanlisib through preclinical to Phase III trials, its unique cellular targets and side effect profile that have poised it as a safer and equally efficacious option when compared to the older-generation oral PI3Kis, and its utility to the clinician as part of the therapeutic armamentarium for relapsed and/or refractory FL.

Keywords: copanlisib, follicular lymphoma, PI3K inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]